The Wnt/b-catenin signaling pathway is activated in many human hepatocellular carcinomas (HCC). We tried to identify the genes involved in carcinogenesis and progression of HCC with b-catenin mutations. We used PCRbased subtractive hybridization to compare gene expression between malignant and benign components of a human HCC occurring in pre-existing adenoma activated for b-catenin. Two of the genes identified belong to the Regenerating gene (REG) family. They encode the Regenerating islet-derived 3 alpha (REG3A/HIP/PAP/ REG-III) and 1 alpha (REG1A) proteins, both involved in liver and pancreatic regeneration and proliferation. Using siRNA directed against b-catenin, we demonstrated that REG3A is a target of b-catenin signaling in Huh7 hepatoma cells. The upregulation of REG3A and REG1A expression is significantly correlated to the b-catenin status in 42 HCC and 28 hepatoblastomas characterized for their b-catenin status. Thus, we report strong evidence that both genes are downstream targets of the Wnt pathway during liver tumorigenesis.
Introduction
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. It is the fifth most frequent cancer worldwide, and its incidence is still rising in Western countries (Parkin et al., 2001; El-Serag, 2002 ). The prognosis is poor. The molecular changes underlying HCC remain largely unknown (Bruix et al., 2004) , although several genetic alterations have been implicated in at least three carcinogenesis pathways, p53, RB and the Wnt/b-catenin signaling pathway (Buendia, 2000; Thorgeirsson and Grisham, 2002) . Deregulation of the Wnt pathway appears to be the most frequent in human HCC and is detected in about 30-40% of these patients (de La Coste et al., 1998; Buendia, 2000) . Mutations affecting two partners of the Wnt pathway have been found in liver cancers. Activating mutations in the b-catenin gene occur mainly in HBV-negative HCC (Laurent-Puig et al., 2001) . The others are mutations that inactivate the AXIN 1, and more rarely the AXIN 2 gene (Satoh et al., 2000; Laurent-Puig et al., 2001; Taniguchi et al., 2002) .
b-catenin is central to the Wnt pathway. It has a structural role in cell-cell adhesion, but is also a transcription cofactor with T-cell factor/lymphoid enhancer factor (TCF/LEF) in the Wnt pathway. In the absence of Wnt signaling, the level of b-catenin is low. b-catenin is phosphorylated at critical NH 2 -terminal residues by the glycogen synthase kinase bound to a scaffolding complex of axin and adenomatous polyposis protein, and subsequently, the phosphorylated protein is degraded by the ubiquitinproteasome system. Wnt stimulation leads to the inactivation of GSK3-b, resulting in the stabilization of b-catenin in the cytoplasm such that it is available to bind the TCF/LEF family of transcription factors and induce target gene expression (Giles et al., 2003) . The genetic program triggered by activation of b-catenin signaling depends on the cellular context (Polakis, 2000; Giles et al., 2003) . The identification of b-catenin target genes would therefore help understand how aberrant b-catenin signaling contributes to liver carcinogenesis. Several studies have investigated the downstream target genes of this pathway. Most of these studies involved differential expression analyses using animal models of hepatocarcinogenesis (Cadoret et al., 2002; Ovejero et al., 2004) , human hepatomas cell lines (Yamamoto et al., 2003) and ex vivo infection of primary human hepatocytes , which expressed an oncogenic form of b-catenin. Very few genes specifically induced in the liver in response to b-catenin have been identified (Cadoret et al., 2002; Yamamoto et al., 2003; Ovejero et al., 2004) . Among them, the glutaminesynthetase gene (GS) appears the most reliable marker (Cadoret et al., 2002; Zucman-Rossi et al., submitted) .
To identify novel candidate b-catenin/TCF transcriptional targets likely to contribute to liver carcinogenesis, we used PCR-based subtractive hybridization to compare gene expression between the different components of a particular human HCC occurring in pre-existing adenoma activated for b-catenin. We report the identification of two genes that belong to the family of the Regenerating (REG) genes that encode growthpromoting lectins: the Regenerating islet-derived 3 alpha (REG3A) (also named HIP/PAP for HepatocarcinomaIntestine-Pancreas/Pancreatitis Associated-Protein) and the Regenerating islet-derived 1 alpha (REG1A) genes (Zhang et al., 2003) . We tested whether the REG3A and REG1A genes are downstream targets of b-catenin and analysed their expression in a panel of primary liver tumors, both HCC and hepatoblastomas (HB), characterized for the presence of b-catenin mutations, and also in colon cancers associated with aberrant b-catenin signaling, from familial adenomatous polyposis (FAP) patients.
Results
Cloning of REG3A and REG1A genes from a rare case of HCC occurring in a b-catenin-mutated adenoma We studied a particularly rare case of HCC to assess the molecular consequences of a dysregulation of the Wnt pathway from benign to malignant stages of hepatic tumor development. This male patient displayed an HCC in a pre-existing liver adenoma in a morphologically normal liver (Figure 1a) . In both components, adenoma and HCC, Wnt/b-catenin signaling was activated as evidenced by the presence of b-catenin not only at the membrane but also in the cytoplasm and more infrequently in the nucleus of tumor cells (Figure 1b) . The GS gene is a reliable marker of Wnt/b-catenin pathway activation in HCC (Cadoret et al., 2002; Zucman-Rossi et al., submitted) , and we confirmed activation of the b-catenin pathway by immunohistochemistry and Northern blot analyses and observed GS overexpression in both stages ( Figures  1c and d) .
The activation of the Wnt pathway in the adenoma and HCC was owing to an in-frame 15 base deletion involving exon 3 (Dcodons 32-36) eliminating the residues that are targets for the destruction of b-catenin (amino acids D32, S33, G34) (Table 1, case no. 5). These tumor specimens were suitable tools to study the altered gene expression owing to aberrant Wnt signaling from the benign to the malignant stages of the liver tumor.
Using the suppression subtractive hybridization technique, two libraries were constructed and screened on the basis of the overexpression in the respective tester tissue. One was expected to be enriched in adenomaspecific genes because adenoma cDNAs have been subtracted by sequences expressed in the non-tumoral tissue; conversely, the other was expected to be more specific for the HCC stage as HCC cDNAs have been subtracted by sequences expressed in the adenomatous tissue.
In all, 78 positive clones corresponding to nine independent genes were isolated from the adenomaenriched library and of 115 positive clones corresponding to 27 independent genes from the carcinoma-enriched library. The reidentification of the GS gene (gene ID 2752) in our suppression subtractive hybridization approach validated the subtraction procedure and served as a positive control. Some of the genes were analysed by real-time RT-PCR to confirm their differential expression in the tissues from which the RNA had been extracted for library construction (data not shown). They included the genes encoding the chitinase 3-like 1 (gene ID 1116), the serine protease inhibitor Kazaltype 1 SPINK1/TATI (gene ID 6690), ubiquitin D (gene ID 10537) and the secreted phosphoprotein 1 or osteopontin (gene ID 6696) (Table 2, Supplementary Information).
Two genes were found to be common to both libraries. They encoded REG3A (cloned under different names HIP/PAP/REG-III, gene ID 5068) (Iovanna et al., 1991; Lasserre et al., 1992; Dusetti et al., 1994) and REG1A (gene ID 5967) (Terazono et al., 1988) . The Overexpression of REG genes in human primary liver tumors C Cavard et al upregulation of REG3A and REG1A gene expression was confirmed in the tissues from which RNA had been extracted for library construction by Northern blot analysis and immunohistochemistry. REG3A and REG1A were not expressed in the non-tumoral liver and were strongly induced both in adenoma and HCC ( Figure 2a) . A strong immunoreactivity was observed for REG3A protein both in the adenoma and HCC ( Figure 2b) ; it was less pronounced for REG1A for which rare foci of stained hepatocytes were detected in both components (Figure 2c ). Interestingly, REG3A and REG1A have similar organization and are tandomly clustered on chromosome 2p12; they encode proteins that are members of the REG family with substantial sequence homology (Zhang et al., 2003) . Their products are secretory proteins of the C-type lectin superfamily that are involved in liver and pancreatic regeneration and proliferation. Consequently, they are candidate for involvement in liver tumorigenesis. The demonstration that they were strongly induced in a b-cateninactivated liver adenoma and carcinoma suggests a common regulation of these genes by the b-catenin pathway.
REG3A mRNA is induced by activation of b-catenin signaling in the Huh7 hepatoma cell line We used the Huh7 hepatoma cell line, which has a wildtype b-catenin status, to test whether the REG3A gene responds to Wnt signaling in vitro. Wnt signaling was activated in Huh7 cells using lithium chloride (LiCl), which inhibits GSK3-b and mimics Wnt signaling by stabilizing b-catenin in its unphosphorylated form (Stambolic et al., 1996) . Stimulation of Wnt signaling by LiCl was monitored by transfecting a TCF reporter (pTOPFLASH) and a control plasmid containing scrambled TCF-binding sites (pFOPFLASH). Cotransfection of Huh7 with pTOPFLASH and an oncogenic Asterisks indicate the patients previously described in Christa et al. (1999) and circles those reported in Terris et al. (1999) . ND ¼ not done
Overexpression of REG genes in human primary liver tumors C Cavard et al b-catenin (DN89b-catenin) led to a 10-fold increase of the basal reporter activity, whereas the increase was approximately 80-fold when cells were treated for 48 h with 20 mM LiCl; no activation of pFOPFLASH activity was observed with either activated b-catenin or with LiCl ( Figure 3a) . Activation of the pTOPFLASH activity following LiCl treatment was substantially reduced both by cotransfection with the plasmid DNTCF4 encoding the dominant-negative form of TCF and transfection of siRNA directed against b-catenin (Verma et al., 2003) ( Figure 3a) ; scrambled siRNA had no effect on the pTOPFLASH activity (data not shown). REG3A mRNA was barely detectable by real-time RT-PCR in untreated cells. REG3A mRNA was slightly induced after 24 h of 20 mM LiCl treatment and gradually increased until 72 h of LiCl treatment (Figure 3b ). This was confirmed by immunocytochemistry for b-catenin and REG3A: the amount of REG3A protein had clearly increased after 72 h of treatment (Figure 3c ). REG1A mRNA was undetectable in untreated Huh7 cells even after LiCl treatment.
To confirm that b-catenin can effectively regulate REG3A expression, we transfected siRNA against b-catenin from the beginning of the LiCl treatment. We confirmed that these previously described siRNA (Verma et al., 2003) strongly inhibit b-catenin signaling induced by LiCl (Figure 3a) and that they had a clear inhibitory effect on REG3A expression at 72 h (Figure 3b ). These results are consistent with the REG3A gene being a downstream target of the Wnt/ b-catenin pathway.
Analysis of REG3A and REG1A expression in human HCCs We tested the relationship between the overexpression of REG3A and REG1A and the activation of the Wnt pathway in vivo, by analysing their expression in a panel of HCCs with known b-catenin status (Table 1) . These series comprises the HCC tumor from which the REG3A gene was initially cloned (Lasserre et al., 1992) ; we characterized a posteriori this tumor for its b-catenin status (Table 1 , case no. 9) and identified a point mutation altering the S33 phosphorylable residue (S33A) of b-catenin. Accordingly, immunohistochemistry revealed that this tumor accumulated b-catenin in the nuclei of hepatocytes (Table 1) .
Of 42 HCCs, 21 (50%) had point mutations or deletions altering target residues for phosphorylation by CK1/GSK3-b, essential for the destruction of b-catenin (Table 1) . Of the 21 mutated HCC, 17 were point mutations, the remaining five were deletions that had arisen in a non-cirrhotic liver (Table 1) .
The expression of REG3A and REG1A genes was analysed by real-time RT-PCR. The overexpression of REG3A and REG1A was observed in most of the HCC analysed (Figure 4a ). In contrast, REG3A and REG1A were undetectable in non-tumoral livers and normal livers (data not shown). REG3A and REG1A gene expression correlated with b-catenin mutation status (P ¼ 0.024 and 0.035, respectively) ( Figure 4a ). The 13 samples expressing REG3A most strongly carried b-catenin mutations. The seven tumors expressing REG1A most strongly had b-catenin mutations. Interestingly, six of them displayed a strong REG3A expression, consistent with coregulation of these two genes. We tested the expression of these genes in benign liver tumors. No expression was detected in focal nodular hyperplasias (n ¼ 8) in which no b-catenin mutation was found. Among the 11 adenomas analysed, expression of these genes is only detected in the three cases exhibiting b-catenin gene deletions (Figure 4b) . A subset of HCCs was then analysed by immunohistochemistry. In all, 10 showed a nuclear and/or a cytoplasmic accumulation of b-catenin, and all 10 exhibited b-catenin mutations (Table 1) . REG3A expression differed among the cases analysed: few cases, all strongly positive for b-catenin, exhibited a marked and diffuse labeling in more than 50% of tumoral cells; most showed weak and heterogeneous staining, for example, in the HCC with intratumoral heterogeneous nuclear staining for b-catenin and REG3A expression was strictly confined to these positive areas (Figure 5a ). Owing to the weakness of the REG1A antibody, in situ hybridization was performed on some HCC samples and on one adenoma sample, which display the strongest expression by real-time RT-PCR (Figure 5b ). Except a weak signal around the bile ducts, no expression is Overexpression of REG genes in human primary liver tumors C Cavard et al observed in the non-tumoral liver for REG3A (data not shown) and REG1A (Figure 5b ). In situ detection of the REG1A mRNA demonstrating its overexpression was further confirmed at the protein level using Western blot analysis (Figure 5c ). These results provide strong evidence for the regulation of REG3A and REG1A genes by b-catenin in human liver tumors.
Analysis of REG3A and REG1A expression in HB and colon adenomas
We assessed the responsiveness of REG1A and REG1A to Wnt signaling, by analysing the expression of these two genes in HB, a pediatric liver tumor for which a high prevalence of b-catenin mutations has been reported (Buendia, 2002) . Among 28 HB cases analysed, Overexpression of REG genes in human primary liver tumors C Cavard et al 19 tumors (66.5%) carried a mutated b-catenin gene. As shown above for HCC, there was a strong correlation between REG3A (P ¼ 0.006) and REG1A (P ¼ 0.026) gene expressions and the presence of b-catenin mutations (Figure 6a ). The level of expression of REG3A in HBs was similar to that in HCCs, but mean REG1A expression was much lower in HBs than in HCCs. This probably reflects context-dependent differences between tumor cells of different origins (Figure 6a ). Concomitant upregulation of REG3A and REG1A gene expression during colorectal carcinogenesis has been reported (Rechreche et al., 1999; Macadam et al., 2000) . In addition, REG1A mRNA is overabundant in colon adenomas from FAP patients (Buckhaults et al., In an HCC exhibiting heterogeneous nuclear staining for b-catenin, the expression of REG3A protein was strictly confined to the areas of tumoral hepatocytes displaying cytosolic and nuclear b-catenin staining (magnification Â 100). (b) Detection of REG1A mRNA by in situ hybridization. Sections were counterstained with Nuclear Fast Red. In situ hybridization shows strong (case nos. 3 and 5) and moderate (case no. 2 and adenoma no. 1) expressions of REG1A by tumoral hepatocytes. The non-tumoral liver does not exhibit any expression except a faint labeling of bile ductular cells as indicated by the arrow (adenoma no. 1) (magnification Â 200). (c) Analysis of REG1A protein by Western blot. Total cell extracts from adjacent non-tumoral and tumoral livers were analysed using SDS-PAGE and immunoblotted with anti-REG1A antibody (Rechreche et al., 1999) . Coomassie Blue staining of proteins is shown.
Overexpression of REG genes in human primary liver tumors C Cavard et al 2001). These tumors display biallelic inactivation of the adenomatous polyposis coli gene (APC), leading to the stabilization and accumulation of wild type b-catenin. We therefore searched for a correlation between the stabilization of b-catenin and the upregulation of REG3A and REG1A in polyps from FAP patients by immunohistochemistry. Among 12 adenomas from four patients, eight displayed perfect confinement of the REG3A and REG1A proteins to adenomatous cells where a strong activation of b-catenin was detected (Figure 6b ).
Discussion
To isolate new b-catenin target genes possibly involved in b-catenin-induced liver tumorigenesis, we used a rare case of HCC that arose in a pre-existing adenoma, and both developed on non-fibrotic liver without clinical evidence of glycogenosis. Both components, adenoma and HCC, display the same b-catenin mutation that was probably the tumorigenic initiating event. Hepatocellular adenoma is a benign liver neoplasm occurring in morphologically normal liver. Mutations of the b-catenin gene are rare events (Chen et al., 2002; Takayasu et al., 2002; Bioulac-Sage et al., 2003) unlike the frequent biallelic inactivation of the gene TCF1 encoding hepatocyte nuclear factor 1 found in 50% of adenomas (Bluteau et al., 2002) . In our case, the b-catenin mutation found in the adenoma was an interstitial deletion involving b-catenin exon 3. Interestingly, the b-catenin mutations in hepatic adenomas described by Chen et al. (2002) were also deletions. Missense mutations are prevalent in human HCC (our results and for a review (see Buendia, 2000) , but in our collection, we found five deletions in HCC occurring in normal, non-cirrhotic liver. HBs are liver tumors occurring in normal liver and show a high prevalence of b-catenin deletions (Takayasu et al., 2001; Buendia, 2002; Taniguchi et al., 2002) . The significance of these observations remains unclear, and it may be of interest to compare tumors from apparently morphologically normal liver displaying b-catenin deletions with those bearing b-catenin point mutations and from a cirrhotic context to determine differences concerning pathogenicity and tumoral development.
Using differential screening, we isolated two genes of the growth-promoting lectin (REG) family, the REG3A and REG1A genes. They were overexpressed in primary liver tumors bearing b-catenin mutations and were probably target genes of the genetically altered b-catenin signaling in these tumors.
We provide various evidence that REG3A and REG1A genes are downstream targets of the Wnt pathway. No expression was detectable in normal and non-cancerous liver; expression of these genes was significantly associated with HCCs and HBs with a mutated b-catenin status. Analysis of polyps from FAP patients with constitutively active Wnt pathway showed that both genes were expressed in epithelial cells strongly expressing activated b-catenin. REG3A expression was induced in Huh7 cells by LiCl treatment, treatment that mimics Wnt signaling, and this expression was abolished by siRNA directed against b-catenin. However, we could not demonstrate that b-catenin directly regulates REG3A promoter activity: REG3A promoter constructs containing up to 2000 bp of regulatory sequences with several LEF/TCF sites showed no responsiveness to b-catenin signaling in transfection experiments (unpublished data). Albeit indirect, the regulation of REG genes expression by Wnt signaling is reinforced by a recent clinical study, which reports in a large series of 265 HCC a strong association between b-catenin mutation and overexpression of REG1A (P ¼ 0.00005) and REG3A (PAP) (Po0.00001) (Yuan et al., 2005) .
REG3A and REG1A belong to the C-lectin family and are tandomly clustered on 2p12. They share structural and some functional properties and are involved in injury, inflammation, diabetes and carcinogenesis (Zhang et al., 2003) . REG3A was first isolated as a pancreatic secretory protein implicated in pancreatic regeneration, and then identified in human HCC (Iovanna et al., 1991; Lasserre et al., 1992; Dusetti et al., 1994) . In the exocrine pancreas, REG3A protein is associated with pancreatic acinar cell protection from oxidative stress and TNF-a-induced pancreatic stress Overexpression of REG genes in human primary liver tumors C Cavard et al (Ortiz et al., 1998; Malka et al., 2000) . It has also been recently reported to behave as a mitogenic factor towards hepatocytes, and an antiapoptotic molecule against TNFa-mediated hepatocyte apoptosis (Simon et al., 2003) . These effects appear to be mediated in part through the activity of the protein kinase A (Simon et al., 2003) . The REG1A gene encodes a protein secreted by the exocrine pancreas, which has been associated with islet cell regeneration and diabetogenesis (Terazono et al., 1988; Watanabe et al., 1994) . Thus, the REG proteins have been reported to be involved in various biological functions including proliferation, and resistance to apoptosis during regeneration, inflammation and tumorigenesis, but nevertheless, their exact biological function(s) remains to be established. Our observation that both REG3A and REG1A proteins are markedly induced in HCC and HB but are not expressed in normal liver suggests that these REG proteins may be involved in human hepatocarcinogenesis. Indeed, it has been reported that the overexpression of the mouse ortholog of REG1A under the rat glucagon promoter led to the development of rare tumors, including HCCs, in transgenic mice consistent with tumor-promoting activity (Yamaoka et al., 2000) . Furthermore, REG1A and REG3A have recently been found overexpressed during rodent liver regeneration after hepatectomy (White et al., 2005) . The REG proteins are associated with inflammation and regenerative processes and therefore we searched for an association between REG expression and clinicopathological features, chronic viral infection or alcohol abuse, but no statistically significant correlation was found.
The expression of REG1A has been also observed in human cholangiocarcinoma and in gastric and colorectal cancers (Buckhaults et al., 2001; Harada et al., 2001; Fukui et al., 2004) . In gastric and colorectal tumors, the expression of this gene is closely correlated to carcinoma invasiveness (Macadam et al., 2000; Dhar et al., 2004) . Whether expression of REG1A and REG3A during hepatocarcinogenesis is a marker of poor prognosis is still unknown. However, a recent clinical data report their differential expression in HCC according to the tumor progression: REG3A would be correlated to a favorable prognosis, whereas expression of REG1A, alone or in combination with REG3A, is associated with a poor outcome (Yuan et al., 2005) . This observation is close to that found in colorectal carcinogenesis where coexpression of these REG genes appears closely linked to the adverse outcome of the disease (Macadam et al., 2000) . This overexpression may also account for the neoplastic progression in HCC with mutational defects in b-catenin. Further studies are required to validate the relationship between the seric production of these proteins and their prognostic value in human HCC.
Materials and methods

Tumor samples
All tumor samples were obtained from surgical liver resections. Access to this material was in agreement with French laws and satisfied the requirements of the local ethics committee. The samples selected for suppression subtractive hybridization analysis were from a 40-year-old man who had developed a HCC on a pre-existing adenoma. Serologies for HBV and HCV were negative and the non-tumoral liver did not show any signs of fibrosis or glycogenosis. HCC RNA was extracted from 25 tumor samples and matched non-tumoral tissue where available, obtained at Cochin Hospital (Paris, France); 17 HCC RNA samples have been reported previously (Christa et al., 1999) . In all, 28 frozen samples of HB obtained by surgical liver resection in different French hospitals were used; 23 of these patients had received preoperative chemotherapeutic treatments (Perilongo et al., 2004) . All samples were characterized for the presence of mutations of the b-catenin gene by PCR with genomic DNA or cDNA as described previously (de La Coste et al., 1998) .
Cell line, transfection and reporter assays
The hepatoma cell line Huh7 was maintained in DMEM with 10% (vol/vol) calf serum. Transient transfections were performed when cells were 60-70% confluent in 12-well plates using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA). The total amount of transfected DNA (2 mg/well) was kept constant by adding pcDNA3. A TK-Renilla plasmid (10 ng) was included in each transfection for monitoring the transfection efficiency. Just before transfection, the culture medium was changed for media supplemented with LiCl 20 mM or sodium chloride (NaCl) 20 mM. Cells were lysed 48 h after transfection and the luciferase and Renilla activities were assayed using Promega's Dual Luciferase Reporter Assay (Promega, Madison, DI, USA). All experiments were performed in duplicate and repeated at least three times. The DN89b-catenin-pCAN expression vector was kindly provided by P Polakis (San Francisco, USA). pTOPFLASH, pFOP-FLASH and the expression plasmid encoding the dominantnegative form of TCF (pDNTCF4) were kindly provided by H Clevers (Utrecht, The Netherlands). Double-stranded siRNAs were purchased from Proligo (Paris, France). For bcatenin, we used the siRNA described previously (Verma et al., 2003) ; the control siRNA was 5 0 -GGCAUAGAUGUAGCUGUAAdTdT-3 0 and its complement, leaving a dTdT 3 0 overhang on both strands. siRNA was transfected into cells according to the manufacturer's instructions with Oligofectamine (Invitrogen, Carlsbad, CA, USA) to result in a final RNA concentration of 150 nM, and cells were harvested after 2 and 3 days, respectively. To determine the effects of siRNA on reporter constructs, the cells were transfected 6 h after siRNA transfection with either pTOPFLASH or pFOPFLASH as described above, and the cells were harvested after 48 h to assay luciferase activity.
Suppression subtractive hybridization (SSH)
For subtractive hybridization, poly(A) þ mRNA was purified using the Micro-FastTrack mRNA isolation kit (Invitrogen, Carlsbad, CA, USA) from total RNA of non-tumoral, adenoma and carcinoma components of liver from the patient described above. Poly(A) þ mRNA (2 mg) were used to prepare cDNA using the SMART cDNA synthesis amplification kit (BD Biosciences Clontech, Palo Alto, CA, USA). Subtractive hybridizations were performed using the PCRSelect Subtractive Hybridization kit (BD Biosciences Clontech, Palo Alto, CA, USA) according to the manufacturer's protocol: cDNA from non-tumoral (driver) and adenoma (tester) tissues and cDNA from adenoma (driver) and carcinoma (tester) tissues were used. The two subtracted cDNA libraries were subcloned into pGEM-T Easy vector (Promega, Madison, DI, USA) and used to transform Electromax DH10B cells (Invitrogen, Carlsbad, CA, USA). Approximately 40 000 clones were plated for both libraries and were screened with the corresponding subtracted tester and driver probes. After secondary screening, 115 clones from the HCC library and 78 clones from the adenoma library were chosen for sequencing.
RNA extraction, Northern blot and RT-PCR analyses Total RNA was extracted from frozen liver or Huh7 cells using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Northern blotting was performed as reported previously (Ovejero et al., 2004) . The human REG3A probe has been described elsewhere (Christa et al., 1999) . The human REG1A probe was produced by RT-PCR with RNA from tumoral colon using specific primers and was further subcloned into pGEM-T Easy vector (Promega, Madison, DI, USA) and sequenced. Reverse transcriptions and real-time RT-PCR analysis were performed as described previously (Cadoret et al., 2002; Ovejero et al., 2004) . The relative target gene expression was normalized on the basis of its 18S ribosomal content and to a calibrator that was a mix of normal tissue included in each run. The calibrator consisted of RNAs extracted from a pool of three colon samples. For each sample, the relative gene expression was expressed as x-fold the relative expression of normalized control tissue. The primer sequences were as follows: REG3A: REG3AF: 5 0 -GGTGAAGAACCCCAGAGGGA-3 0 ; REG3AR: 
Immunohistochemistry
Immunostaining was performed on 5 mm sections of formalinfixed, paraffin-embedded liver. Sections were incubated with specific antibodies for 1 h. These primary antibodies were monoclonal anti-b-catenin (1/100, BD Biosciences) (Cadoret et al., 2002) , monoclonal antiglutamine-synthetase (1/200, BD Biosciences) (Cadoret et al., 2002) , polyclonal pre-HIP (1/400) (Christa et al., 1999) and monoclonal anti-REG1A (1/200, a generous gift from C Figarella, Marseille, France) (BernardPerrone et al., 1999) . Bound antibody was visualized using the immunoperoxidase protocol (Vectastain ABC kit, Vector Burlingame, CA, USA).
Western blotting
Western blots were performed as previously described after separation of total proteins (10 mg) through 14% sodium dodecyl sulfate-polyacrylamide gel (Ovejero et al., 2004) , and probed with anti-REG1A-antibody (1/500, a generous gift from JL Iovanna, Marseille, France) (Rechreche et al., 1999) .
In situ hybridization The REG1A sense and antisense probes were obtained as described above after subcloning into pGEM-T Easy vector (Promega, Madison, DI, USA). In situ hybridization was performed as described previously (Andreu et al., 2005 ) using a digoxigenin-labeled probe and detected using an anti-digoxigenin antibody (1/4000) (Roche, Basel, Switzerland). Sections were counterstained with Nuclear Fast Red (Vector laboratories, Burlingame, CA, USA).
